Skip to content

US · TRAW · BIOTECHNOLOGY

Traws Pharma, Inc. (TRAW) intrinsic value and stock valuation

$0.18as of 2026-11-21 · Mkt cap 4.86M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Traws Pharma, Inc. DCF and intrinsic value

InvestorsCraft values TRAW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TRAW’s statements →

Traws Pharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Newtown, PA 18940 trawspharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.79M+64.7% 5y CAGRd
20112025
Net income
$9.17M
20112025
Free cash flow
-$-20.77M
20112025
Total equity
-$-630K
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.79M$230K$230K$230K$230K
Operating income-$-17.88M-$-49.35M-$-20.3M-$-19.63M-$-16.5M
Net income$9.17M-$-54.67M-$-18.95M-$-18.96M-$-16.16M
EPSd$1.09M-$-35.27M-$-22.56M-$-22.57M-$-24.12M
Operating cash flow-$-18.18M-$-29.79M-$-17.93M-$-16.29M-$-19.49M
Capital expenditure-$-2.58M$0.00-$-10K$0.00$0.00
Free cash flow-$-20.77M-$-29.79M-$-17.95M-$-16.29M-$-19.49M
Total assets$10.6M$25M$22.7M$39.4M$55.5M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-3.82M-$-21.34M-$-20.82M-$-38.76M-$-55.07M
Total equity-$-630K-$-31.63M$10.7M$28.3M$46.1M
Cash and short-term investments$3.82M$21.3M$20.8M$38.8M$55.1M
Income statement
20252024202320222021
Revenue$2.79M$230K$230K$230K$230K
Cost of revenue$0.00$10K$0.00$0.00$0.00
Gross profit$2.79M$210K$230K$230K$230K
Research and development expenses$12.1M$130.3M$11.4M$11.4M$7.3M
Selling, general and administrative expenses$8.52M$12.3M$9.09M$8.45M$9.43M
Other expenses$0.00-$-93.04M$0.00$0.00$0.00
Operating expenses$20.7M$49.6M$20.5M$19.9M$16.7M
Cost and expenses$20.7M$49.6M$20.5M$19.9M$16.7M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$60K$10K$20K$10K$10K
Ebitda-$-17.81M-$-166.51M-$-20.28M-$-19.61M-$-16.48M
Operating income-$-17.88M-$-49.35M-$-20.3M-$-19.63M-$-16.5M
Total other income/expenses, net$27.1M-$-117.17M$1.35M$660K$330K
Income before tax$9.17M-$-166.52M-$-18.95M-$-18.96M-$-16.16M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$9.17M-$-54.67M-$-18.95M-$-18.96M-$-16.16M
Weighted average shares outstanding$8.23M$1.55M$840K$840K$670K
Weighted average diluted shares outstanding$8.38M$1.55M$840K$840K$670K
Balance sheet
20252024202320222021
Cash and short-term investments$3.82M$21.3M$20.8M$38.8M$55.1M
Net receivables$3.79M$1.76M$20K$30K$30K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.98M$25M$22.7M$39.4M$55.4M
Property, plant and equipment, net$10K$10K$20K$20K$40K
Goodwill and intangible assets$2.53M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.64M$10K$20K$30K$50K
Total assets$10.6M$25M$22.7M$39.4M$55.5M
Accounts payable$5.65M$8.19M$5.62M$3.86M$2.76M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$230K$230K$230K$230K
Total current liabilities$11.2M$11.5M$9.22M$8.05M$6.12M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$2.56M$2.79M$3.02M$3.24M
Total non-current liabilities$100K$45.1M$2.79M$3.02M$3.24M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$11.3M$56.6M$12M$11.1M$9.36M
Common stock$90K$40K$210K$210K$210K
Retained earnings-$-639.98M-$-649.15M-$-482.63M-$-463.68M-$-444.72M
Accumulated other comprehensive income (loss)$10K-$-40K-$-20K-$-30K-$-10K
Total equity-$-630K-$-31.63M$10.7M$28.3M$46.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-3.82M-$-21.34M-$-20.82M-$-38.76M-$-55.07M
Cash flow statement
20252024202320222021
Net income$9.17M-$-54.67M-$-18.95M-$-18.96M-$-16.16M
Depreciation and amortization$60K$10K$20K$10K$10K
Stock-based compensation$730K$0.00$1.3M$1.17M$580K
Change in working capital-$-2.03M-$-6.57M-$-300K$1.48M-$-3.59M
Accounts receivable-$-2.03M-$-1.75M$10K-$0.00$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-610K$650K$1.76M$1.1M-$-2.08M
Net cash provided by operating activities-$-18.18M-$-29.79M-$-17.93M-$-16.29M-$-19.49M
Investments in property, plant and equipment-$-2.58M$0.00-$-10K$0.00$0.00
Acquisitions, net$0.00-$-3.65M$0.00$0.00$0.00
Net cash used for investing activities-$-2.58M-$-3.65M-$-10K$0.00$0.00
Common stock issued$5.61M$34M$0.00$0.00$55M
Common stock repurchased-$-2.4M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.2M$34M$0.00$0.00$55.6M
Net change in cash-$-17.52M$520K-$-17.94M-$-16.31M$36.1M
Cash at end of period$3.82M$21.3M$20.8M$38.8M$55.1M
Operating cash flow-$-18.18M-$-29.79M-$-17.93M-$-16.29M-$-19.49M
Capital expenditure-$-2.58M$0.00-$-10K$0.00$0.00
Free cash flow-$-20.77M-$-29.79M-$-17.95M-$-16.29M-$-19.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Traws Pharma, Inc.

        Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

        CEO
        Iain D. Dukes
        Employees
        7
        Beta
        1.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Traws Pharma, Inc. (TRAW)?

        InvestorsCraft does not currently publish an intrinsic value for TRAW. How the IC value is calculated.

        Is TRAW undervalued?

        InvestorsCraft does not publish an undervaluation signal for TRAW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.